- cafead Aug 10, 2022 at 11:42: PM
via MaaT Pharma is not getting out from under an FDA clinical hold for its microbiome drug any time soon.
MaaT013, in development for steroid-resistant acute graft-versus-host disease (aGvHD), was placed on hold a year ago, halting a phase 3 trial in the U.S. The FDA had concerns about several clinical and manufacturing issues.
article source
MaaT013, in development for steroid-resistant acute graft-versus-host disease (aGvHD), was placed on hold a year ago, halting a phase 3 trial in the U.S. The FDA had concerns about several clinical and manufacturing issues.
article source